Across TCGA pan-cancer cohorts, RASGEF1A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RASGEF1A data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RASGEF1A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RASGEF1A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, UCEC, and BLCA are the cancer types where RASGEF1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.174	0.781	<.001	15	view →
UCEC	OS	Median	All	1.000	0.660	.025	14	view →
BLCA	OS	Median	All	0.231	0.618	.048	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RASGEF1A tumor-vs-normal RNA expression · all RASGEF1A data types